Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases.

Casey DL, Pitter KL, Imber BS, Lin A, Chan TA, Beal K, Yamada Y, Feldman DR, Yang TJ.

J Neurooncol. 2019 May;142(3):523-528. doi: 10.1007/s11060-019-03123-0. Epub 2019 Feb 15.

PMID:
30771201
2.

Endoluminal high-dose-rate brachytherapy for locally recurrent or persistent esophageal cancer.

Taggar AS, Pitter KL, Cohen GN, Schattner M, Gerdes H, Markowitz AJ, Ilson D, Brady P, Cuaron JJ, Goodman KA, Wu AJ.

Brachytherapy. 2018 May - Jun;17(3):621-627. doi: 10.1016/j.brachy.2018.01.010. Epub 2018 Feb 26.

3.

Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

Casey DL, Pitter KL, Kushner BH, Cheung NV, Modak S, LaQuaglia MP, Wolden SL.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1204-1209. doi: 10.1016/j.ijrobp.2018.01.008. Epub 2018 Jan 9.

4.

Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.

Herting CJ, Chen Z, Pitter KL, Szulzewsky F, Kaffes I, Kaluzova M, Park JC, Cimino PJ, Brennan C, Wang B, Hambardzumyan D.

Glia. 2017 Dec;65(12):1914-1926. doi: 10.1002/glia.23203. Epub 2017 Aug 24.

5.

High Precision Imaging of Microscopic Spread of Glioblastoma with a Targeted Ultrasensitive SERRS Molecular Imaging Probe.

Huang R, Harmsen S, Samii JM, Karabeber H, Pitter KL, Holland EC, Kircher MF.

Theranostics. 2016 May 7;6(8):1075-84. doi: 10.7150/thno.13842. eCollection 2016.

6.

Corticosteroids compromise survival in glioblastoma.

Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S, Dai C, Ozawa T, Chang M, Chan TA, Beal K, Bishop AJ, Barker CA, Jones TS, Hentschel B, Gorlia T, Schlegel U, Stupp R, Weller M, Holland EC, Hambardzumyan D.

Brain. 2016 May;139(Pt 5):1458-71. doi: 10.1093/brain/aww046. Epub 2016 Mar 28.

7.

Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo.

Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, Carlin SD, La Rocca G, Lyashchenko S, Ploessl K, Rohle D, Omuro AM, Cross JR, Brennan CW, Weber WA, Holland EC, Mellinghoff IK, Kung HF, Lewis JS, Thompson CB.

Sci Transl Med. 2015 Feb 11;7(274):274ra17. doi: 10.1126/scitranslmed.aaa1009.

8.

Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging.

Harmsen S, Huang R, Wall MA, Karabeber H, Samii JM, Spaliviero M, White JR, Monette S, O'Connor R, Pitter KL, Sastra SA, Saborowski M, Holland EC, Singer S, Olive KP, Lowe SW, Blasberg RG, Kircher MF.

Sci Transl Med. 2015 Jan 21;7(271):271ra7. doi: 10.1126/scitranslmed.3010633.

9.

The SHH/Gli pathway is reactivated in reactive glia and drives proliferation in response to neurodegeneration-induced lesions.

Pitter KL, Tamagno I, Feng X, Ghosal K, Amankulor N, Holland EC, Hambardzumyan D.

Glia. 2014 Oct;62(10):1595-607. doi: 10.1002/glia.22702. Epub 2014 Jun 4.

10.

Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis.

Ortiz B, Fabius AW, Wu WH, Pedraza A, Brennan CW, Schultz N, Pitter KL, Bromberg JF, Huse JT, Holland EC, Chan TA.

Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):8149-54. doi: 10.1073/pnas.1401952111. Epub 2014 May 19.

11.

In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift.

Halliday J, Helmy K, Pattwell SS, Pitter KL, LaPlant Q, Ozawa T, Holland EC.

Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5248-53. doi: 10.1073/pnas.1321014111. Epub 2014 Mar 24.

12.

Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth.

Pietras A, Katz AM, Ekström EJ, Wee B, Halliday JJ, Pitter KL, Werbeck JL, Amankulor NM, Huse JT, Holland EC.

Cell Stem Cell. 2014 Mar 6;14(3):357-69. doi: 10.1016/j.stem.2014.01.005.

13.

The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas.

Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL, Huse JT, Cajola L, Zanetti N, DiMeco F, De Filippis L, Mangiola A, Maira G, Anile C, De Bonis P, Reynolds BA, Pasquale EB, Vescovi AL.

Cancer Cell. 2012 Dec 11;22(6):765-80. doi: 10.1016/j.ccr.2012.11.005.

14.

Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma.

Pitter KL, Galbán CJ, Galbán S, Tehrani OS, Li F, Charles N, Bradbury MS, Becher OJ, Chenevert TL, Rehemtulla A, Ross BD, Holland EC, Hambardzumyan D.

PLoS One. 2011 Jan 18;6(1):e14545. doi: 10.1371/journal.pone.0014545. Erratum in: PLoS One. 2011;6(1). doi: 10.1371/annotation/66641ad6-afb9-4d3c-ade6-73fcd5aab061. Saeed-Tehrani, Omid [corrected to Tehrani, Omid Saeed].

15.

Dual role of proapoptotic BAD in insulin secretion and beta cell survival.

Danial NN, Walensky LD, Zhang CY, Choi CS, Fisher JK, Molina AJ, Datta SR, Pitter KL, Bird GH, Wikstrom JD, Deeney JT, Robertson K, Morash J, Kulkarni A, Neschen S, Kim S, Greenberg ME, Corkey BE, Shirihai OS, Shulman GI, Lowell BB, Korsmeyer SJ.

Nat Med. 2008 Feb;14(2):144-53. doi: 10.1038/nm1717. Epub 2008 Jan 27.

Supplemental Content

Loading ...
Support Center